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Abstract
A nonpsychoactive cannabinoid cannabidiol (CBD) has been shown to exert potent anti-
inflammatory and antioxidant effects and has recently been reported to lower the incidence of diabetes
in nonobese diabetic mice and to preserve the blood-retinal barrier in experimental diabetes. In this
study we have investigated the effects of CBD on high glucose (HG)-induced, mitochondrial
superoxide generation, NF-κB activation, nitrotyrosine formation, inducible nitric oxide synthase
(iNOS) and adhesion molecules ICAM-1 and VCAM-1 expression, monocyte-endothelial adhesion,
transendothelial migration of monocytes, and disruption of endothelial barrier function in human
coronary artery endothelial cells (HCAECs). HG markedly increased mitochondrial superoxide
generation (measured by flow cytometry using MitoSOX), NF-κB activation, nitrotyrosine
formation, upregulation of iNOS and adhesion molecules ICAM-1 and VCAM-1, transendothelial
migration of monocytes, and monocyte-endothelial adhesion in HCAECs. HG also decreased
endothelial barrier function measured by increased permeability and diminished expression of
vascular endothelial cadherin in HCAECs. Remarkably, all the above mentioned effects of HG were
attenuated by CBD pretreatment. Since a disruption of the endothelial function and integrity by HG
is a crucial early event underlying the development of various diabetic complications, our results
suggest that CBD, which has recently been approved for the treatment of inflammation, pain, and
spasticity associated with multiple sclerosis in humans, may have significant therapeutic benefits
against diabetic complications and atherosclerosis.
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The majority of diabetic complications are associated with pathophysiological alterations in
the vasculature. Micro- and macrovascular diseases are the most common causes of morbidity
and mortality in patients with diabetes mellitus. Microvascular complications involve
retinopathy and nephropathy, the leading causes of blindness and renal failure. Atherosclerosis
is the most common macrovascular complication of diabetes, which increases the risk for
stroke, myocardial infarction, and peripheral artery disease, the latter being the leading cause
of limb amputation in civilized countries. Hyperglycemia has been implicated in the activation
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of numerous key mechanisms/pathways including oxidative (5,50) and nitrosative stress (38,
41,50), advanced glycation end products (4), aldose reductase (23,35), protein kinase C (24),
and nuclear enzyme poly(ADP-ribose) polymerase (3,39,42,51), which in concert result in
endothelial dysfunction in diabetic blood vessels underlying the development of various
diabetic complications. One of the key early events in the pathogenesis of atherosclerosis is
the adhesion of monocytes to the endothelium followed by transmigration into the
subendothelial space (16,17). Studies have demonstrated increased leukocyte-endothelial
interactions with monocytes from diabetic patients (16,29), in animal models of diabetes (16,
54), and also in cells exposed to high glucose (HG) in vitro (13,27,49,52). Importantly, the
hyperglycemia/HG-induced augmentation of leukocyte adhesion to the endothelium through
upregulation of cell surface expression of adhesion molecules and transendothelial migration
(TEM) has been reported to be dependent on NF-κB activation (21,32).
Cannabinoids, components of the Cannabis sativa (marijuana) plant, are known to exert potent
anti-inflammatory, immunomodulatory and analgesic effects through activation of
cannabinoid-1 and -2 (CB1 and CB2) receptors located in the central nervous system and
immune cells (28,37). The limitation of the therapeutic utility of the major cannabinoid, Δ9-
tetrahydrocannabinol, is the development of psychoactive effects through central nervous
system CB1 receptor (37). In contrast, cannabidiol (CBD), one of the most abundant
cannabinoids of Cannabis sativa with reported antioxidant, anti-inflammatory, and
immunomodulatory effects is well tolerated without side effects when chronically administered
to humans (7,11) and is devoid of psychoactive properties due to a low affinity for the CB1
and CB2 receptors (37,53).
Here we have studied the effects of CBD on HG-induced mitochondrial superoxide generation,
NF-κB activation, inducible nitric oxide synthase (iNOS) expression, nitrotyrosine formation
[footprint of peroxynitrite generation (38)], upregulation of adhesion molecules ICAM-1 and
VCAM-1, monocyte-endothelial adhesion, TEM of monocytes, and disruption of endothelial
barrier function in human coronary artery endothelial cells (HCAECs). Our results may have
important relevance for the prevention/treatment of diabetic complications and atherosclerosis.
MATERIALS AND METHODS
Reagents
1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-moepholinyl-1H-pyrazole-3-
carboxamide (AM 281) and 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-
methoxyphenyl) methanone (AM 630) were purchased from Tocris Bioscience (Ellisville,
MO). N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-3-pyrazole-
carboxamide (SR 141716A; designated as SR1) and {N-[1S]-endo-1,3,3-trimethylbicyclo
[2.2.1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-
carboxamide} (SR 144528; designated as SR 2) was from Research Triangle Institute
(Research Triangle Park, NC). CBD was obtained from either Tocris Bioscience or isolated
from hashish as described earlier (15). Sources of all the other reagents used in the experiments
are mentioned in the text wherever appropriate.
Cell culture
HCAECs and growth medium were purchased from Cell Applications (San Diego, CA).
HCAECs were grown in HCAEC growth medium in cell culture dishes coated with 0.2%
gelatin. HCAECs were used for the experiments between passages 3–7. Human monocytic
cell line (THP-1) was obtained from American Type Culture Collection and was grown in
RPMI 1640 medium supplemented with 2 mM L-glutamine, 10 mM HEPES, 10% fetal bovine
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serum, 100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen, CA). The cells were
maintained at 37°C in an incubator containing 5% CO2-95% room air.
Cell surface ICAM-1 and VCAM-1 expression assay
Cell surface expression of ICAM-1 and VCAM-1 was measured using in situ ELISA as
described (2). In brief, HCAECs were grown in 96-well plates coated with 0.2% gelatin. The
cells were treated with either 5 or 30 mM D-glucose (designated as HG) alone for 48 h (33).
In some experiments, cells were pretreated with either specific CB1 antagonists SR1/AM 281
or CB2 antagonists SR2/AM 630 for 1 h, followed by continued incubation with HG ± CBD
for 48 h.
Western immunoblot analysis of ICAM-1 and VCAM-1 expression
After treatment, cells were washed two times with PBS, and total cell lysate was prepared using
radioimmunoprecipitation assay lysis buffer (Pierce Biotechnology) supplemented with
cocktail of protease inhibitors (Roche). Protein (25 μg) was resolved in 12% SDS-PAGE and
probed with either mouse anti-human ICAM-1/VCAM-1 (1:1,000, R&D systems), and the
blots were incubated overnight at 4°C. After being washed, the blots were incubated with
secondary antibody goat anti-mouse horseradish peroxidase (Pierce, 1:5,000) for 1 h at room
temperature (RT). The blots were then developed with SuperSignal enhanced
chemiluminescent substrate solution (Pierce). To verify equal loading, blots were stripped
(Pierce) and reprobed with β-actin (Chemicon).
Monocyte adhesion assay
The determination of monocyte adhesion to the endothelial cells was conducted using human
THP-1 cells as described (27). In brief, HCAECs were grown to confluence in 24-well plates
and treated with HG/CBD ± CB1/CB2 antagonists. THP-1 cells were labeled with 1.5 μM
calcein-AM (Molecular Probes; Invitrogen, CA) for 1 h at 37°C in RPMI 1640 containing 1%
FBS. Labeled THP-1 cells (105/100 μl) were then added to HCAECs and incubated for 1 h at
37°C in an incubator containing 5% CO2-95% room air. After incubation, the medium
containing monocytes was aspirated and the monolayer was gently washed with PBS three
times to remove the unbound monocytes. The adherent monocytes were documented using an
Olympus IX 81 fluorescent microscope using a × 10 objective with a × 1.5 digital zoom. Three
fields were captured per experimental condition. Individual treatments were performed in
duplicates, and the entire set of experiments was repeated at least three times. The number of
adherent THP-1 cells was counted using National Institutes of Health ImageJ software, and
the values were expressed as adhered cells per field.
Monocyte TEM assay
HCAECs were grown to confluence on 0.2% gelatin-coated 3.0-μm polyethylene terepthalate
track-etched cell culture inserts (BD Biosciences). The assays were performed essentially as
described with minor modifications to the protocol (44). Confluent HCAECs were treated with
HG/CDB ± CB1/CB2 antagonists as mentioned in the aforementioned experiments. THP-1
cells were then labeled with 2 μM Cell Tracker Green 5-chloromethylfluorescein diacetate
(CMDFA, Molecular Probes) according to the protocol supplied by the manufacturer. Labeled
THP-1 cells (3 × 105/200 μl) were added to the upper compartment of the cell culture insert,
and the lower compartment of the insert contained 0.5 ml of RPMI 1640. Subsequently, the
monocytes were allowed to transmigrate for 4 h at 37°C in an environment of 5% CO2-95%
room air. Finally, the culture inserts were removed, and the fluorescence in the lower chamber
was measured using the Victor-Wallac Multilabel counter (Perkin Elmer) with excitation at
492 nm and emission at 571 nm. The fluorescence of the lower chamber was proportional to
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the number of monocytes that were transmigrated. The monocyte TEM was expressed as a
percentage, and the set of experiments was repeated independently three times.
Immunofluorescece staining for vascular endothelial cadherin expression
HCAECs were grown to confluence in glass chamber slides (Lab-Tek, Nalgene Nunc) and
treated with HG alone or pretreated with CBD for 1 h followed by incubation with HG for 48
h. After the incubation, cells were fixed in 4% paraformaldehyde for 20 min at RT.
Subsequently, the cells were permiabilized with 0.2% Triton X-100 for 20 min at RT. After
being washed with PBS, the cells were incubated with anti-human vascular endothelial
cadherin (VE-cadherin) antibody (1:150; mouse monoclonal, R&D Systems) for 5 h at 4°C.
In the subsequent step, the cells were probed with goat anti-mouse FITC conjugate (1:250,
Pierce) for 1 h at RT. The nucleus was counterstained with propidium iodide (Molecular
Probes). Images were obtained using a fluorescent microscope (Olympus IX 81) at a ×20
objective with a ×1.5 digital zoom.
In vitro vascular permeability assay
HCAECs were grown to confluence in polycarbonate cell culture inserts (0.4 μm pore size, 6.5
mm diameter) in 24-well companion plates (BD Biosciences). The assays were performed as
described earlier (48). The growth medium was removed and replaced with 100 μl of 2% FBS
growth factor free medium (upper chamber) and 0.5 ml in the lower chamber. Cells were
pretreated with either CBD or CB1/CB2 antagonists for 1 h and continued incubation with HG
for 48 h. Subsequently, the medium was removed and replaced with 100 μl of serum and growth
factor free medium (upper chamber) containing FITC-dextran (40 kDa, Molecular Probes).
This step was followed by incubation of the inserts at 37°C in an environment of 5% CO2-95%
room air for 45 min. The fluorescence intensities of the solution in the lower chamber were
measured using Victor-Wallac Multilabel Counter System (Perkin Elmer) with excitation at
485 nm and emission at 535 nm.
Analysis of NF-κB activation
NF-κB activation was analyzed by measuring inhibitory κB-α factor (IκB-α) degradation and
subsequent translocation of NF-κB (p65) to the nucleus using Western blot assays. HCAECs
were grown to confluence in 100 mm cell culture dishes. The cells were then treated with either
HG or CBD alone for 48 h or pretreated with CB1/CB2 antagonists followed by incubation
with HG and/or CBD for 48 h. Subsequently, nuclear and cytoplasmic extracts were prepared
using mammalian nuclear protein extraction reagent (NPER; Pierce) by following the
manufacturer’s instructions. Nuclear protein (30 μg) or cytoplasmic extracts (20 μg) were
resolved on a 12% SDS-PAGE and then transferred to nitrocellulose membrane. After being
blocked, the membranes were probed with human anti-IκB-α (rabbit monoclonal, Cell
Signaling Technology) in the case of cytoplasmic extract or with anti-human NF-κB (p65)
(mouse monoclonal, Invitrogen) in the case of the nuclear extract blots at 1:1,000 and 1:1,500
dilutions, respectively, and incubated overnight at 4°C. Subsequently, the membranes were
washed and incubated with appropriate secondary antibodies for 1 h at RT. Finally, the bands
were visualized using West Pico chemiluminescence substrate reagent (Pierce). The protein
concentration in the cellular extracts was measured using the Bio-Rad Lowry assay kit. The
band densities were determined using Image Quant software (Molecular Devices). IκB-α
degradation was expressed as the ratio of IκB-α to β-Actin, whereas the NF-κB expression was
denoted by percent increase after normalizing the NF-κB expression with histone 2B as the
loading control. Furthermore, HG-induced NF-κB activation was also confirmed by using
immunoflourescene assay, indicating the nuclear translocation of NF-κB.
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Determination of mitochondrial superoxide generation
HCAECs were seeded in 0.2% gelatin-coated 12-well culture dishes and allowed to reach
confluence. The cells were then preconditioned in growth factor free medium containing 2%
FBS for 4 h, followed by treatments with 5 mM glucose, 30 mM HG, and 30 mM D-mannitol
for 48 h. In some experiments, cells were incubated with CBD (4 μM) alone for 48 h, or added
1 h before, the treatment with HG and incubated for 48 h. At the end of incubation, MitoSOX
red (5.0 μM; Molecular Probes/Invitrogen) was added to the cells and incubated further for 15
min at 37°C in an atmosphere of 5% CO2-95% room air as described (43,45). Subsequently,
cells were collected by trypsinization and washed in PBS supplemented with 1% BSA, and
measurements were performed using FACS caliber system (BD Biosciences). MitoSOX red
was excited by laser at 488 nm, and the data were collected at 585/42 nm (FL2) channel. The
data were presented by histogram of mean intensity of MitoSOX fluorescence.
iNOS expression and 3-nitrotyrosine accumulation
HCAECs were treated with normal glucose, CBD (4 μM), or HG alone for 48 h or pretreated
with CBD for 1 h followed by treatment with HG for 48 h. After incubation, iNOS expression
[anti-human iNOS (mouse monoclonal) BD Biosciences] and 3-nitrotyrosine (3-NT) formation
(rabbit polyclonal, Cayman Chemicals) were analyzed by Western blot analysis and
immunofluorescence staining.
Statistical analysis
All values are represented as means ± SE. Statistical significance of the data was assessed by
paired Student’s t-test or one-way ANOVA as appropriate. P < 0.05 was considered significant.
RESULTS
CBD inhibits HG-induced upregulation of ICAM-1 and VCAM-1
HG treatment of HCAECs resulted in a marked upregulation of ICAM-1 (Fig. 1A) and
VCAM-1 (Fig. 1B) expression by ~6.0- and 5.5-fold, respectively, when compared with normal
glucose-treated cells. This upregulation of ICAM-1 and VCAM-1 expression was dose-
dependently reduced by CBD (0–6 μM) pretreatment (Fig. 1, A and B). The effect of CBD was
not preventable by either CB1 or CB2 antagonists, which by themselves had no effect on HG-
induced increased adhesion molecule expression (Fig. 1, C and D). L-Glucose (30 mM) or D-
mannitol (30 mM) had no effect on the upregulation and expression of ICAM-1 and VCAM-1
(data not shown). Similar results were obtained by using Western immunoblot assay (Fig. 1,
E and F).
CBD attenuates HG-induced increased monocyte adhesion to the endothelial cells
The representative fields containing monocytes adhered to the endothelial cells with the
indicated treatments are shown in Fig. 2A. HG treatment of HCAECs resulted in a ~4.5-fold
increase in monocyte adhesion when compared with normal glucose-treated cells (Fig. 2B).
Pretreatment of HCAECs with CBD (4 μM) significantly inhibited HG-induced monocyte
adhesion to endothelial cells (Fig. 2, A and B), which was not preventable by CB1/CB2
antagonists.
CBD decreases HG-induced monocyte TEM
HG treatment resulted in a marked increase in the monocyte TEM ~3.5 fold when compared
with normal glucose-treated cells (Fig. 3). When HCAECs were pretreated with CBD, it
significantly reduced the HG-induced increased monocyte TEM, an effect not preventable by
either CB1 or CB2 antagonists. CB1 or CB2 antagonists had no effect on HG-induced TEM by
themselves.
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CBD attenuates HG-induced disruption of the endothelial barrier function of HCAECs in vitro
HG induced a marked loss of VE-cadherin staining, which was attenuated by CBD pretreatment
(Fig. 4A). HG treatment resulted in increased endothelial permeability, characterized by
increased seepage of dextran-FITC (40 kDa), which was attenuated by CBD pretreatment, an
effect not preventable by either CB1 or CB2 antagonists (Fig. 4B). CB1 or CB2 antagonists had
no effect on HG-induced disruption of endothelial barrier function by themselves.
CBD moderately attenuates mitochondrial superoxide generation by HG in HCAECs in vitro
HG treatment but not 30 mM D-mannitol (not shown) markedly enhanced mitochondrial
superoxide generation (by 3.5-fold) compared with normal glucose in HCAECs. CBD (4 μM)
pretreatment attenuated the HG-induced superoxide generation by 23% (Fig. 4C).
CBD attenuates HG-induced increased NF-κB activation in HCAECs
Treatment of HCAECs with HG led to marked degradation of IκB-α (cytoplasm; Fig. 5A) and
increased translocation of NF-κB (p65) to the nucleus (Fig. 5, B and C). CBD pretreatment
largely prevented NF-κB activation, an effect not preventable by either CB1 or CB2 antagonists.
CBD attenuates HG-induced increased iNOS expression and 3-NT formation
HG treatment of HCAECs resulted in significant increase in the iNOS expression (~3.5 fold)
(Fig. 6, A and B) and 3-NT formation (Fig. 6C) when compared with normal glucose-treated
cells. All these phenotypic changes induced by HG were inhibited by CBD.
DISCUSSION
In the present study, we have evaluated the effects of CBD, a nonpsychoactive component of
marijuana, on HG-induced mitochondrial superoxide generation, NF-κB activation, iNOS
expression, nitrotyrosine formation, upregulation of adhesion molecules ICAM-1 and
VCAM-1, monocyte-endothelial adhesion, TEM of monocytes, and disruption of endothelial
barrier function in HCAECs. We demonstrate that CBD attenuates HG-induced mitochondrial
superoxide generation, NF-κB activation, nitrotyrosine formation, upregulation of iNOS and
adhesion molecules ICAM-1 and VCAM-1, TEM of monocytes, monocyte-endothelial
adhesion, and disruption of the endothelial barrier function in HCAECs by a mechanism
independent from CB1 and CB2 receptors.
Consistently, CBD has been shown to exert anti-inflammatory and antioxidant effects both in
vitro and in various preclinical models of neurodegeneration and inflammatory disorders,
independent from classical CB1 and CB2 receptors (6,8,14,19,20,22,25,31,37,46,53). CBD is
devoid of psychoactive effects due to a low affinity for the central nervous system CB1
receptors (37,53) and is well tolerated when chronically administered to humans (7,11). CBD
has been approved for the treatment of inflammation, pain, and spasticity associated with
multiple sclerosis in humans since 2005 (1,37). Furthermore, CBD has recently been reported
to lower the incidence of diabetes in nonobese diabetic mice (55) and to preserve the blood-
retinal barrier in experimental diabetes (12).
Numerous epidemiological studies have identified diabetes mellitus as a major risk factor for
atherosclerotic cardiovascular diseases such as stroke and coronary heart disease (26).
Hyperglycemia triggers the activation of numerous key mechanisms/pathways, such as reactive
oxygen species (5) and reactive nitrogen species (40,41), poly(ADP-ribose) polymerase (3,
36,39,42,51), protein kinase C (24), advanced glycation end products (4), and aldose reductase
(23,35), eventually leading to endothelial dysfunction in diabetic blood vessels underlying the
development of various diabetic complications.
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Superoxide production plays a significant role in the pathogenesis of the diabetes-associated
endothelial dysfunction (5,18,34,47). The cellular sources of superoxide anion are multiple
and include NADH/NADPH and xanthine oxidases, the mitochondrial respiratory chain, the
arachidonic acid cascade (including lipoxygenase and cycloxygenase), and microsomal
enzymes (5,18,34,47). Among these pathways, mitochondrial generation of superoxide
appears to play the most crucial role in diabetic complications (34). Superoxide can also be
converted to hydrogen peroxide (H2O2) by superoxide dismutase (SOD), and previous studies
have suggested that H2O2 plays a central role in NF-κB activation in coronary artery endothelial
cells (9,10). Hyperglycemia-induced superoxide generation might also favor increased
expression of iNOSs through the activation of NF-κB, which increases the generation of nitric
oxide. Superoxide anion interacts with nitric oxide, forming the potent cytotoxin peroxynitrite,
which attacks various biomolecules in the vascular endothelium, vascular smooth muscle, and
myocardium, leading to cardiovascular dysfunction via multiple mechanisms (38,41). The
pathogenetic role of nitrosative stress and peroxynitrite and downstream mechanisms is not
limited to the diabetes-induced cardiovascular dysfunction but also contributes to the
development and progression of diabetic nephropathy, retinopathy, and neuropathy in both
experimental animals and humans (38,41).
An increased adhesion of leukocytes (especially monocytes) to the endothelium followed by
transmigration into the subendothelial space is a crucial early event in the pathogenesis of
atherosclerosis and certain inflammatory disorders [e.g., inflammatory vascular diseases (16,
17)]. HG concentration increases the surface expression of adhesion molecules ICAM-1 and
VCAM-1 in endothelial cells, adhesion of endothelial cells to monocytes, and TEM of
monocytes in vitro, phenomena related to increased reactive oxygen species generation and
NF-κB activation (13,21,27,32,49,52). Studies have also demonstrated increased leukocyte-
endothelial interactions with monocytes from diabetic patients (16,29) and in animal models
of diabetes (16,54). Recently, Li et al. (30) have reported that macrophages and vascular smooth
muscle cells isolated from diabetic mice exhibited proatherogenic properties, such as enhanced
adhesion and migration that were largely dependent on NF-κB activation (30).
Consistent with these previous reports, we found that HG increased mitochondrial superoxide
generation, 3-NT formation, NF-κB activation, upregulation of iNOS and adhesion molecules
ICAM-1 and VCAM-1, TEM of monocytes, and monocyte-endothelial adhesion in HCAECs
(Fig. 6D). HG also decreased endothelial barrier function measured by increased permeability
and diminished expression of VE-cadherin in HCAECs (Fig. 6D). Remarkably, all the above-
mentioned effects of HG were attenuated by CBD (Fig. 6D). Since reactive oxygen species/
peroxynitrite/NF-κB pathway and downstream effectors, such as poly(ADP-ribose)
polymerase-1, play important roles in the destruction of insulin-secreting pancreatic β-cells
(reviewed in Ref. 38), it is conceivable that the above-mentioned anti-inflammatory effects of
CBD could contribute to the recently observed antidiabetic effects in nonobese diabetic mice
(55).
Collectively, our results suggest that the nonpsychoactive cannabinoid CBD have significant
therapeutic benefits against diabetic complications and atherosclerosis by attenuating HG-
induced mitochondrial superoxide generation, increased NF-κB activation, upregulation of
iNOS and adhesion molecules, 3-NT formation, monocyte-endothelial adhesion, TEM of
monocytes, and disruption of the endothelial barrier function. This is particularly encouraging
in light of the excellent safety and tolerability profile of CBD in humans.
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Fig. 1.
Effect of cannabidiol (CBD) on high glucose (HG)-induced increased ICAM-1 and VCAM-1
expressions in human coronary artery endothelial cells (HCAECs). Cells were treated with
either normal glucose (5 mM) or HG (30 mM) alone for 48 h or pretreated with CBD at indicated
concentrations followed by treatment with HG for 48 h, and cell-surface ELISA was then
performed by measuring absorbance at 450 nm as described in MATERIALS AND
METHODS. A: effect of CBD on HG-induced increased ICAM-1 expression. *P < 0.001 vs.
5 mM glucose; #P < 0.001 vs. HG; ‡P < 0.05 vs. HG. OD, optical density (n = 9). B: effect of
CBD on HG-induced increased VCAM-1 expression. *P < 0.001 vs. 5 mM glucose; #P < 0.001
vs. HG; ‡P < 0.05 vs. HG (n = 9). Cells were treated with either normal glucose, HG, or CBD
alone for 48 h or pretreated with either cannabinoid-1 or -2 (CB1 or CB2, respectively)
antagonists (1 μM each) followed by treatment with either HG alone or in combination with
CBD, and cell surface ELISA was performed for ICAM-1 (C) or VCAM-1 (D) expression
(n = 9). *P < 0.0001 vs. normal glucose; #P < 0.001 vs. HG (n = 3). E: representative ICAM-1
immunoblot from 3 identical blots depicting the effect of indicated treatments on ICAM-1
expression. *P < 0.001 vs. 5 mM glucose or CBD (4 μM alone); #P < 0.01 vs. HG. F:
representative VCAM-1 immunoblot from 3 identical blots depicting the effect of indicated
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treatments on VCAM-1 expression. *P < 0.01 vs. 5mM glucose or CBD (4 μM alone); #P <
0.01 vs. HG (n = 3).
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Fig. 2.
Effect of CBD on HG-induced increased monocyte adhesion to endothelial cells. A:
representative pictures of monocytes adhered to HCAECs. HCAECs were either treated with
normal glucose, HG for 48 h, or pretreated with CBD (4 μM) or either CB1 or CB2 antagonists
followed by incubation with HG alone or in combination with CBD, and adhesion assays were
performed as described in the MATERIALS AND METHODS. B: quantification data for
monocyte adhered to endothelial cells from 3 independent experiments. *P < 0.001 vs. normal
glucose; #P < 0.001 vs. HG.
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Fig. 3.
Effect of CBD on HG-induced increased monocyte transendothelial migration (TEM).
HCAECs were treated with either normal glucose, HG, or CBD for 48 h or pretreated with
CBD or either CB1 or CB2 antagonists followed by incubation with HG ± CBD and continued
incubation for 48 h, and monocyte adhesion TEM assays were performed as outlined in
MATERIALS AND METHODS. *P < 0.001 vs. control or normal glucose; #P < 0.001 vs.
HG (n = 6).
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Fig. 4.
Effect of CBD on HG-induced barrier dysfunction and mitochondrial superoxide production.
A: representative images of immunofluorescence staining for vascular endothelial cadherin
expression in HCAECs from 3 independent experiments with similar results. B: quantitative
data for in vitro transcellular hyperpermeability of FITC-dextran induced by HG and the effect
of CBD on HG-induced barrier dysfunction in HCAECs. *P < 0.001 vs. normal glucose; #P
< 0.001 vs. HG (n = 6). C: effect of CBD on HG induced mitochondrial superoxide production.
Mitocondrial superoxide generation was then determined by FACS calibur system using
MitoSOX as described in MATERIALS AND METHODS.Shown are representative flow
cytometry data of mitochondrial superoxide formation by HG and partial attenuation CBD.
Quantifications were performed from mean intensity of MitoSOX fluorescence from 3
independent experiments. Error bars represent standard deviation. C, left: numbers in graphs
represent mean fluorescence intensity. *P < 0.001 vs. normal glucose; #P < 0.05 vs. HG (n =
3).
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Fig. 5.
Effect of CBD on HG-induced NF-κB activation. A, top: HCAECs were treated as indicated,
cytoplasmic extracts were prepared, and Western immunoblot assays were performed to
determine inhibitory κB-α factor (IκB-α) degradation. Shown is the representative blot from 3
independent experiments with similar results. A, bottom: quantification of IκB-α degradation
in the cytosol. *P < 0.001 vs. control; #P < 0.001 vs. HG. B, top: representative blot for NF-
κB (p65) expression in nuclear extracts prepared after treatments as indicated. B, bottom:
quantification data for NF-κB expression in nucleus after normalization with histone. *P <
0.01 vs. control; #P < 0.01 vs. HG (n = 3). C: HG-induced nuclear translocation of NF-κB
(p65), indicating its activation and its inhibition by CBD. Note intense nuclear staining of p65
in HG-treated cells. Shown are representative images from 5 independent experiments yielding
similar results.
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Fig. 6.
Effect of CBD on HG-induced inducible nitric oxide (NO) synthase (iNOS) expression and 3-
nitrotyrosine (3-NT) formation, proposed protective mechanisms of CBD. A: HCAECs were
treated with either normal glucose, CBD (4 μM), HG alone for 48 h or pretreated with CBD
followed by HG treatment for 48 h. Total cell lysates were prepared, and 25 μg of protein were
resolved on 12% SDS-PAGE gels and probed with anti-human iNOS (monoclonal, used at
1:1,000 dilution; BD Biosciences). Shown is the representative image from 3 separate
experiments with identical results. *P < 0.001 vs. 5 mM glucose; #P < 0.01 vs. HG. B: HCAECs
were treated as described above, and iNOS expression was analyzed by immunofluorescene
staining (mouse monoclonal anti-human iNOS at 1:150 dilution). The nuclei were
counterstained with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI; Molecular Probes,
Invitrogen). Shown are representative images from 3 separate experiments. C: 3-NT formation
in HG-treated cells and effects of CBD by immunofluorescence assay. Nuclei were
counterstained with DAPI. Shown are images from 3 independent experiments with identical
results. D: proposed protective mechanisms of CBD against HG-induced endothelial cell
inflammatory response and barrier disruption. Mitochondrion is considered to be the major
source of hyperglycemia-induced increased superoxide anion production; however, other
sources such as xanthine and NAD(P)H oxidases, cyclooxygenase, and uncoupled NOS may
also contribute to this process under certain conditions. Hyperglycemia-induced superoxide
generation might also favor increased expression of iNOS through activation of NF-κB, which
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increases the generation of NO. Superoxide anion quenches NO, thereby reducing the efficacy
of a potent endothelium-derived vasodilator system. Superoxide can also be converted to
hydrogen peroxide by SOD and interact with NO to form a reactive oxidant peroxynitrite
(ONOO–), which induces cell damage via lipid peroxidation, inactivation of enzymes and other
proteins by oxidation and nitration, and activation of nuclear enzyme poly(ADP-ribose)
polymerase (PARP-1). Red arrows/lines indicate activation, and black lines indicate inhibition.
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